Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
B 32.95 0.06% 0.02
VCEL closed up 0.83 percent on Friday, June 2, 2023, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.06%
Bollinger Band Squeeze Range Contraction 0.06%
NR7 Range Contraction 0.06%
Gapped Up Strength 0.06%
Bollinger Band Squeeze Range Contraction 0.89%
Stochastic Reached Oversold Weakness 0.89%
Strong but Oversold Other 0.89%
BB Squeeze + Lower Band Touch Range Contraction 0.89%
Lower Bollinger Band Touch Weakness 0.89%
Oversold Stochastic Weakness 0.89%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Reversed from Down 12 minutes ago
Gap Down Closed about 1 hour ago
60 Minute Opening Range Breakout about 2 hours ago
Gap Down Partially Closed about 3 hours ago
Down 3% about 3 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Vericel Corporation Description

Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Stem Cell Cell Therapy Heart Failure Knee Burns Myopathy Cardiomyopathy Cartilage Osteochondritis Dissecans Severe Diseases

Is VCEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 35.73
52 Week Low 17.31
Average Volume 242,023
200-Day Moving Average 27.46
50-Day Moving Average 31.44
20-Day Moving Average 33.27
10-Day Moving Average 33.39
Average True Range 1.38
RSI (14) 51.69
ADX 15.07
+DI 23.27
-DI 20.22
Chandelier Exit (Long, 3 ATRs) 31.61
Chandelier Exit (Short, 3 ATRs) 35.16
Upper Bollinger Bands 34.76
Lower Bollinger Band 31.78
Percent B (%b) 0.39
BandWidth 8.95
MACD Line 0.38
MACD Signal Line 0.60
MACD Histogram -0.2215
Fundamentals Value
Market Cap 1.5 Billion
Num Shares 45.4 Million
EPS 0.00
Price-to-Earnings (P/E) Ratio 10976.67
Price-to-Sales 9.59
Price-to-Book 9.99
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.21
Resistance 3 (R3) 34.20 33.77 33.99
Resistance 2 (R2) 33.77 33.45 33.77 33.92
Resistance 1 (R1) 33.35 33.24 33.14 33.36 33.85
Pivot Point 32.92 32.92 32.81 32.92 32.92
Support 1 (S1) 32.50 32.60 32.29 32.51 32.01
Support 2 (S2) 32.07 32.39 32.07 31.94
Support 3 (S3) 31.65 32.07 31.87
Support 4 (S4) 31.66